Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 31.91

+1.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Douglas who wrote (215)	7/29/1997 8:32:00 AM
From: Douglas	of 455

The NIH Small Business Innovative Research and Small Business Technology Transfer grant programs provide an opportunity for ALL key players in biomedical research to benefit. SBIR grants provide $850,000 (Phase I and II) or more and STTR grants $600,000 (Phase I and II) or more in research dollars to catalyze the commercialization of innovative projects that will benefit public health. Further, these grants offer company scientists an opportunity to pursue innovative projects for which company support may not be available, and they promote and foster partnerships with collaborators, including academic investigators. By serving as a collaborator, consultant, or principal investigator (for STTR), an academic investigator can gain long-term financial and scientific benefits. Collaboration with a company also offers access to company resources and expertise and possibly jobs for graduate students and postdoctoral fellows. Further, NIH SBIR and STTR grants can add value to an academic institution's intellectual property. With rapidly expanding biological knowledge, even large corporations can develop only a limited number of promising lead ideas. Large pharmaceutical corporations often look to small biotechnology companies for the initial development of embryonic technology. Thus, the end of a successful project for a small biotechnology company is often the beginning of R&D for a large pharmaceutical corporation. NIH small business grants can help bridge the needs of both by providing early-stage funding for research that adds value to an idea and promoting partnerships that lead to a marketable product.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next